Your browser is no longer supported. Please, upgrade your browser.
Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.25 Insider Own0.30% Shs Outstand95.15M Perf Week-4.05%
Market Cap11.95B Forward P/E- EPS next Y-5.29 Insider Trans-57.94% Shs Float83.08M Perf Month-0.29%
Income-461.60M PEG- EPS next Q-1.38 Inst Own90.50% Short Float7.36% Perf Quarter65.25%
Sales69.40M P/S172.19 EPS this Y-38.70% Inst Trans0.86% Short Ratio3.81 Perf Half Y58.87%
Book/sh11.53 P/B10.89 EPS next Y-0.20% ROA-35.60% Target Price149.76 Perf Year191.19%
Cash/sh9.97 P/C12.60 EPS next 5Y46.09% ROE-46.90% 52W Range35.98 - 147.63 Perf YTD235.44%
Dividend- P/FCF- EPS past 5Y-28.70% ROI-39.70% 52W High-14.93% Beta2.99
Dividend %- Quick Ratio9.80 Sales past 5Y-10.60% Gross Margin- 52W Low249.06% ATR6.02
Employees514 Current Ratio9.80 Sales Q/Q24.80% Oper. Margin- RSI (14)47.54 Volatility4.74% 4.33%
OptionableYes Debt/Eq0.14 EPS Q/Q-10.30% Profit Margin- Rel Volume1.63 Prev Close123.66
ShortableYes LT Debt/Eq0.14 EarningsNov 07 AMC Payout- Avg Volume1.60M Price125.59
Recom2.20 SMA20-2.78% SMA50-0.38% SMA20046.25% Volume2,612,918 Change1.56%
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Oct-30-17Initiated FBR & Co. Buy $150
Oct-02-17Upgrade Goldman Neutral → Buy
Sep-21-17Reiterated Needham Buy $85 → $125
Sep-15-17Initiated Instinet Reduce
Jun-22-17Resumed Jefferies Buy $102
May-15-17Reiterated Chardan Capital Markets Buy $95 → $110
Mar-30-17Initiated UBS Neutral $55
Feb-09-17Reiterated Needham Buy $98 → $68
Feb-02-17Initiated Ladenburg Thalmann Buy
Dec-19-16Reiterated Chardan Capital Markets Buy $89 → $69
Nov-30-16Reiterated Chardan Capital Markets Buy $73 → $89
Nov-16-16Reiterated Needham Buy $137 → $98
Nov-10-16Resumed Leerink Partners Mkt Perform
Oct-07-16Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-06-16Reiterated Stifel Hold $68 → $36
Dec-17-17 09:09AM  The 3 Best Biotech Stocks of 2017 Motley Fool
Dec-15-17 03:00PM  Alnylam Gets Some Welcome News Motley Fool
11:44AM  The FDA Just Blessed A Hemophilia Trial From This Biotech Investor's Business Daily
10:35AM  Alnylam gets FDA OK to restart hemophilia drug trial after patient's death American City Business Journals
09:21AM  Stocks to Watch: CSX, Hess, Adobe, Costco, Aclaris Therapeutics The Wall Street Journal
08:32AM  Alnylam shares surge 5% after FDA lifts hold on hemophilia drug MarketWatch
07:43AM  FDA allows Alnylam to restart hemophilia treatment trials Reuters
07:14AM  FDA allows Alnylam to restart hemophilia treatment trials Reuters
07:02AM  Sanofi: FDA lifts clinical hold on fitusiran GlobeNewswire
07:00AM  FDA Lifts Clinical Hold on Fitusiran Business Wire
Dec-12-17 07:00AM  Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis Business Wire
Dec-11-17 02:25PM  Alnylam Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALNY) : December 11, 2017 Capital Cube
07:00AM  Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis Business Wire
Dec-08-17 08:06AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Dec-07-17 04:00PM  Alnylam to Webcast Presentation at BMO Capital Markets Prescriptions for Success Healthcare Conference Business Wire
07:57AM  Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : December 7, 2017 Capital Cube
Dec-06-17 12:47PM  Why Alnylam Pharmaceuticals Rose 12.7% in November Motley Fool
Dec-04-17 09:03AM  What Analysts Recommend for United Therapeutics in November 2017 Market Realist -6.77%
Dec-01-17 08:10AM  Todays Research Reports on Stocks to Watch: Seattle Genetics and Alnylam Pharmaceuticals ACCESSWIRE
Nov-30-17 02:35PM  Alnylam CEO backs inflation-based drug price hikes, welcomes Amazon's foray into health care CNBC
01:18PM  Alnylam CEO John Maraganore: It's hard to justify drug pr... CNBC Videos
10:00AM  Alnylam Chief Makes Pricing Pledges Before Drug Is Even Approved Forbes
Nov-29-17 04:59PM  Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017 Motley Fool
Nov-24-17 08:15PM  Alnylam Pharmaceuticals Inc (ALNY) CEO John Maraganore Sold $9.6 million of Shares GuruFocus.com
Nov-21-17 12:29PM  A Look at Alnylam Pharmaceuticals" Rolling NDA GuruFocus.com
10:38AM  Alnylam's RNAi Candidate Gains Breakthrough Therapy Status Zacks
Nov-20-17 07:00AM  U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy Business Wire
Nov-17-17 09:01AM  Alnylam Starts Rolling NDA Submission for RNAi Candidate Zacks
07:50AM  New Research: Key Drivers of Growth for Great Plains Energy, Flowers Foods, Hasbro, Acadia Healthcare, DXC Technology, and Alnylam Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-16-17 04:00PM  Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
01:40PM  Arbutus LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran GlobeNewswire
10:59AM  Why is Alnylam's (ALNY) Stock Up More Than 200% this Year? Zacks
07:00AM  Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis Business Wire
Nov-15-17 03:37PM  Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next Motley Fool
Nov-14-17 03:44PM  Ionis Pharmaceuticals Inc. Sets Itself Up for Growth Motley Fool
10:05AM  Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA Zacks
Nov-13-17 08:02PM  Alnylam Pharmaceuticals Prices Public Offering of Common Stock Business Wire -7.77%
05:22PM  Arbutus LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA) GlobeNewswire
07:30AM  European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis Business Wire
07:00AM  Alnylam Pharmaceuticals Announces Proposed Public Offering of $675,000,000 of Common Stock Business Wire
05:33AM  Edited Transcript of ALNY earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 01:30PM  The Forbes Healthcare Summit 2017: The Draft Agenda Forbes
10:01AM  Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017 Capital Cube
Nov-09-17 04:00PM  Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia Business Wire
11:46AM  ETFs with exposure to Alnylam Pharmaceuticals, Inc. : November 9, 2017 Capital Cube
08:54AM  The Market In 5 Minutes: Adidas, Jobless Claims, And More Benzinga
Nov-08-17 11:47AM  Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates Zacks
Nov-07-17 05:03PM  Alnylam reports 3Q loss Associated Press
04:00PM  Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity Business Wire
12:23PM  Is Alnylam Pharmaceuticals Inc (ALNY) As Financially Strong As Its Balance Sheet Indicates? Simply Wall St.
07:30AM  Featured Company News - Alnylam Shares Positive Preliminary Results from Ongoing Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 ACCESSWIRE
07:00AM  Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs) Business Wire
Nov-06-17 03:25PM  What's in Store for Madrigal (MDGL) This Earnings Season? Zacks
10:33AM  What's in Store for Catalyst (CPRX) This Earnings Season? Zacks
08:54AM  Is a Surprise Coming for Alnylam Pharmaceuticals (ALNY) This Earnings Season? Zacks
07:30AM  Unknown BTCY May Have Big Upside Ahead of Likely Near-Term FDA Approval ACCESSWIRE
07:00AM  The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran Business Wire
Nov-03-17 05:01PM  Ionis Rebounds After Beating Alnylam To Drug Application In Europe Investor's Business Daily
11:00AM  Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 (PH1) Business Wire
08:43AM  Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Alnylam Pharmaceuticals ACCESSWIRE
Nov-02-17 05:35PM  Alnylam Spikes Prodding Ionis' Pitfall On Rare-Disease Drug Trial Investor's Business Daily +10.32%
05:26PM  Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today Motley Fool
02:34PM  Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today Motley Fool
01:58PM  Alnylam shares hit all-time high as rare disease drug continues to impress American City Business Journals
12:17PM  Alnylam RNAi drug reverses progress of rare fatal disease -study Reuters
10:48AM  Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy GlobeNewswire
10:45AM  Alnylam RNAi drug reverses progress of rare fatal disease - study Reuters
10:45AM  Alnylam and Sanofi Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy Business Wire
Nov-01-17 09:02AM  Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals Market Realist
07:33AM  Alnylam Saw Serious Adverse Event in Fitusiran Phase 2 OLE Study Market Realist
Oct-31-17 04:50PM  Alnylam Is Preparing for Commercial Launch of Patisiran Market Realist
04:00PM  Alnylam to Webcast Presentations at Upcoming November Investor Conferences Business Wire
03:20PM  Patisiran Expected to Become Key Growth Driver for Alnylam Market Realist
01:55PM  Is Alnylam Pharmaceuticals Inc (ALNY) Worth $122.96 Based On Its Intrinsic Value? Simply Wall St.
01:48PM  What Analysts Recommend for Alnylam Pharmaceuticals and Peers Market Realist
08:32AM  Alnylam Pharma The New 'Alpha Generator' Stock Pick At FBR Benzinga
Oct-30-17 04:00PM  Alnylam to Webcast Conference Call Discussing Third Quarter 2017 Financial Results Business Wire
03:13PM  How Celgene, Gilead's Pricing Woes Continue To Haunt Biotech Stocks Investor's Business Daily
07:50AM  Biotechs Lead Health Sector, But Are Those Glory Days Over? Investor's Business Daily
Oct-26-17 12:28PM  Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss Zacks
08:08AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Oct-24-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Oct-23-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Oct-20-17 07:00AM  Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors Business Wire
Oct-18-17 11:35AM  Alnylam to partner with Scangos-led biotech on infectious disease drugs American City Business Journals
11:09AM  UPDATE 1-Alnylam, Vir partner on RNAi-based hep B treatment Reuters
11:07AM  Alnylam, Vir partner on RNAi-based drugs for infectious diseases Reuters
07:15AM  Alnylam's stock set to rally after exclusive license deal with Vir Biotechnology MarketWatch
07:01AM  Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases Business Wire
Oct-17-17 08:06AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Oct-13-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Oct-09-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Oct-05-17 11:28AM  Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September Motley Fool
Oct-03-17 12:20PM  Analysts Act on Health Care Stocks GuruFocus.com
Oct-02-17 08:05AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Sep-29-17 10:54AM  Why Biotech and Tech Will Push Stocks Higher In 4Q Investopedia
Sep-27-17 08:05AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Sep-26-17 08:00AM  Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) Business Wire
Sep-25-17 09:57AM  Gene Therapy: A Big Week for Many Names Barrons.com
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KEATING LAURIESVP, GC and SecretaryDec 01Option Exercise77.4030,0002,322,00041,500Dec 05 05:47 PM
KEATING LAURIESVP, GC and SecretaryDec 01Sale135.8930,0004,076,82311,500Dec 05 05:47 PM
MARAGANORE JOHNChief Executive OfficerNov 22Option Exercise31.3973,4152,304,497223,125Nov 24 06:55 PM
MARAGANORE JOHNChief Executive OfficerNov 22Sale130.9073,4159,609,736149,710Nov 24 06:55 PM
MARAGANORE JOHNChief Executive OfficerNov 15Option Exercise31.3974,0002,322,860223,710Nov 17 05:35 PM
MARAGANORE JOHNChief Executive OfficerNov 15Sale126.8674,0009,387,951149,710Nov 17 05:35 PM
Ausiello Dennis ADirectorNov 02Option Exercise30.0920,000601,80020,000Nov 03 08:14 PM
Ausiello Dennis ADirectorNov 02Sale130.0020,0002,600,0000Nov 03 08:14 PM
Vaishnaw AkshayEVP, R&DOct 30Option Exercise21.3533,666718,76945,201Nov 01 05:33 PM
Vaishnaw AkshayEVP, R&DOct 30Sale121.4633,6664,088,96711,535Nov 01 05:33 PM
Greene Barry EPresidentOct 02Option Exercise21.3585,3161,821,497185,744Oct 04 07:45 PM
Greene Barry EPresidentOct 02Sale125.0085,31610,664,500100,428Oct 04 07:45 PM
Greene Barry EPresidentSep 21Option Exercise12.3311,844146,042100,428Sep 22 05:05 PM
Greene Barry EPresidentSep 20Option Exercise31.3976,8152,411,223165,399Sep 22 05:05 PM
Greene Barry EPresidentSep 20Sale100.0076,8157,681,50088,584Sep 22 05:05 PM
Vaishnaw AkshayEVP, R&DJun 13Option Exercise19.191,66832,00711,965Jun 15 05:45 PM
Sanofi10% OwnerMay 31Buy71.87297,50121,381,39710,554,134Jun 01 07:41 PM
KEATING LAURIESVP, GC and SecretaryMay 30Buy65.3511,500751,50211,500May 31 05:22 PM
Vaishnaw AkshayEVP, R&DMay 23Option Exercise21.3511,000234,85021,297May 25 06:39 PM
Vaishnaw AkshayEVP, R&DMay 23Sale75.0011,000825,00010,297May 25 06:39 PM
Mason MichaelVP, Finance and TreasurerMay 16Option Exercise14.049,375131,5889,375May 17 06:45 PM
Mason MichaelVP, Finance and TreasurerMay 16Sale70.009,375656,2500May 17 06:45 PM
Vaishnaw AkshaySVP, R&DMay 15Option Exercise28.8743,7501,262,87343,047May 17 06:31 PM
Vaishnaw AkshaySVP, R&DMay 15Sale65.0043,7502,843,75010,297May 17 06:31 PM
SHARP PHILIP ADirectorFeb 01Option Exercise31.2925,000782,250165,795Feb 03 04:32 PM
SHARP PHILIP ADirectorFeb 01Sale39.8025,000995,125140,795Feb 03 04:32 PM
SHARP PHILIP ADirectorJan 25Option Exercise31.3915,000470,850155,795Jan 27 04:10 PM
SHARP PHILIP ADirectorJan 25Sale37.9515,000569,250140,795Jan 27 04:10 PM
SHARP PHILIP ADirectorJan 18Option Exercise15.9115,000238,650155,795Jan 20 04:12 PM
SHARP PHILIP ADirectorJan 18Sale37.8315,000567,456140,795Jan 20 04:12 PM
MARAGANORE JOHNChief Executive OfficerJan 05Option Exercise18.661,34025,004149,710Jan 06 04:22 PM
Vaishnaw AkshayEVP, R&DDec 30Option Exercise19.619,547187,25115,297Jan 04 05:30 PM